Efficacy and Safety of Cyclosporine Combined with CAG Chemotherapy in Treatment of Refractory Acute Myeloid Leukemia
Objective:To observe the efficacy and safety of cyclosporine combined with CAG chemotherapy in the treatment of refractory AML.Methods:Taking 123 patients with refractory AML admitted to The First Affiliated Hospital of Henan University from May 2020 to March 2022 as the research objects.They were divided into combination group(62 cases)and chemotherapy group(61 cases)with drawing lots.Patients of two groups received CAG chemotherapy(ACLA+A-arc+G-CFS)uniformly.The combination group used cyclosporine with chemotherapy.After the treatment,the patients were followed up for half a year.The short-term and long-term efficacy and adverse drug reactions of the two groups were compared.Results:After treatment,the total effective rate in the combined group was 88.71％,which was higher than that 73.77％of chemotherapy group,with statistically significant difference(x2=7.323,P＜0.05).WBC,platelet transfusion and the duration of agranulocytosis were lower than those in the chemotherapy group,with statistically significant difference(x2=3.121,12.510,11.231,3.423;P＜0.05).During the follow-up period,the relapse rate and mortality rate of the combined group were higher than those of the chemotherapy group,and the QOL-BREF score was higher than that of the chemotherapy group,with statistically significant difference(x2=5.643,4.884;t=5.412;P＜0.05).The incidence of side effects after treatment in the combination group was 11.29％,which was slightly higher than that in the chemotherapy group(9.84％),with no statistically significant difference(x2=0.111,P＞0.05).Conclusion:The combination of CAG chemotherapy and cyclosporine adjuvant therapy for refractory AML patients can effectively enhance the short and long term efficacy,promote the improvement of symptoms and prolong the life cycle of patients.The combined use of this drug does not significantly enhance the risk of side effects,and has high safety.
万方数据
维普
